22 results
Thumbnail

D2.182 - Low-dose oral food challenge (OFC) in a pediatric day-care hospital: a pre-immunotherapy approach for managing nut-allergies in children

Thumbnail

D2.183 - Assessment of Incidence and Onset of Eosinophilic Esophagitis during the clinical development of Peanut (Arachis hypogaea) Allergen Powder-dried non-fat protein for oral immunotherapy

Thumbnail

D2.184 - Trends in aeroallergen immunotherapy prescription

Thumbnail

D2.185 - Ultrarush honeybee venom immunotherapy in patients with monoclonal mast cell activation syndrome: two case reports

Thumbnail

D2.186 - Toxicity Assessment of Repeated Doses of Apis mellifera Venom for Immunotherapy

Thumbnail

D2.187 - Can the Conjunctival Allergen Provocation Test Improve Long-Term Adherence to Subcutaneous Allergen-Specific Immunotherapy?

Thumbnail

D2.188 - Low allergenicity of food allergen by Galactomannan Conjugation and immunotherapeutic efficacy of peanut-galactomannan conjugate in a mouse model of peanut allergy

Thumbnail

D2.189 - Eosinophilic Esophagitis Induced by Sublingual Immunotherapy (SLIT): A Rare but Emerging Side Effect

Thumbnail

D2.190 - Unmasking Autoimmunity: A Case of Thyroiditis Emerging After Allergy Immunotherapy

Thumbnail

D2.191 - Autoimmune Disease Unmasked by Allergic Immunotherapy: A Case of Systemic Lupus Erythematosus (SLE) After SCIT

Thumbnail

D2.192 - IgE-Mediated Immunotherapy-Induced Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Thumbnail

D2.193 - Oral Induction of Tolerance to Cow's Milk Protein Allergy in Omani Children: A Retrospective Analysis

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years